bioactive compounds

Montisera Strengthens Executive Management Team By Appointing New Ceo

Montisera Strengthens Executive Management Team By Appointing New Ceo

(Montisera, Turku; November 5th, 2019) – Montisera Ltd, a Finnish development company focused on developing and commercializing bioactive compounds, have announced today that it has appointed Jukka Mäkelä as company’s new CEO. At the same time, he has been appointed as CEO of Montisera’s daughter companies Montinutra Ltd and Montipharma Ltd.

Jukka Mäkelä has 30 years’ professional experience. He has worked as Vice President, Business Development in Oriola Corporation and as Head of Business Area and Partner in Accenture. He is Chairman of the Board of Herralan Saha. He holds a Master’s degree in Business Economics.

Mäkelä’s appointment is a clear reflection of the company’s strategic direction. Montisera is ready to take next step to realize the potential value of its strong portfolio of patents. Montinutra will start production of natural bioactive extracts, that will be used in wide range of applications in food, feed and technochemical industries. Montipharma will be heading to clinical development phases of promising medicine to treat variety of dependency disorders, including alcoholism and game dependency, and functional food ingredients for lower urinary tract symptoms, including prostate related disorders.

“Montisera ticks so many right boxes - clean natural bioactive products, biogradeable products to replace plastics, increasing value of forest industry side streams, circular economy. I’m thrilled for the opportunity to be part of the journey to scale up these businesses”, says Mäkelä.

Mäkelä has started in his position in October 2019 and will be responsible for deploying Montisera´s strategy in developing and commercializing novel drug candidates and bioactive compounds with health benefits for food and pharma sectors.

“We are delighted to welcome Jukka to our passionate Executive Management Team. His appointment comes at an exciting time for Montisera as we are heading into a new area of investing in production and entering into clinical development” says Matti Kurvinen, Chairman of the Board of Montisera.

Heikki Vuorikoski, founder of Montisera, will continue in Montisera in his current position as Business Development Director.

Montinutra and Montipharma are both issuing shares from November 4th, 2019 onwards.

For further information please contact:

Jukka Mäkelä, CEO, Montisera, tel. +358 46 8765223

Matti Kurvinen, Chairman of the Board, Montisera, tel. +358 40 5047845